Veradermics, Incorporated Common Stock (MANE)

Veradermics' shares are up nearly 270% since its IPO earlier this year.

Veradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss. The randomized, double-blind, placebo-controlled study enrolled 536

Veradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment. Chief Executive Officer Dr. Reid Waldman said t

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.